Cooperative Agreement R43CA180316

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...

The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging And Dosimetry, LLC, a company based in Baltimore, Maryland. The funding supports the development of a prototype web/cloud-based quantitative SPECT reconstruction software system for use in clinical trials and ultimately clinical dosimetry for radiopharmaceutical therapy (RPT). The software aims to enable accurate quantitative imaging...

Federal Grant Award Summary The National Cancer Institute awarded a $736,168 Project Grant to Sloan-Kettering Institute for Cancer Research (award date: August 1, 2025; completion date: July 31, 2030) under the Cancer Treatment Research program (CFDA 93.395) to develop novel antibody-drug conjugates (ADCs) and antibody-oligonucleotide conjugates (AOCs) designed to enhance radiotherapy efficacy through antigen-specific radiosensitization. The research focuses on delivering potent DNA damage...

This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...

Paramita Therapeutics Inc. received a $353,009 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395), awarded September 24, 2025, with completion targeted for August 31, 2026. The project focuses on developing novel multivalent prostate-specific membrane antigen (PSMA)-targeted taxane-conjugates to address bone metastases in prostate cancer. The research involves synthesizing multivalent drug conjugates (MDCs)...

Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $431,222 to the Research Foundation of the City University of New York (RFCUNY), doing business as RFCUNY–Hunter College, under the Cancer Treatment Research program (CFDA 93.395) on May 13, 2026, with completion targeted for April 30, 2028. This project grant supports the development of radiotherapeutic paradigms for desmoplastic small round cell tumor (DSRCT), an extremely rare abdominal and pelvic soft tissue...

Federal Project Grant Award Summary Georgia TECH Research Corp will conduct integrated research to disrupt redox and lipid metabolic adaptations that confer radiotherapy resistance in head and neck cancer (HNC) patients. Funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) with $595,041 obligated, this five-year project (July 1, 2026–June 30, 2031) will deliver computational modeling, experimental validation, and preclinical testing services...

The University of Chicago received a $421,685 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded July 1, 2026, with completion targeted for June 30, 2028. The grant funds research to develop TET3 cytosine demethylase inhibition as a radiosensitization strategy for mismatch repair-proficient (pMMR) colorectal cancer (CRC). The research employs CRISPR loss-of-function models in CRC cell lines and syngeneic tumor models to...

Grant Award Summary Fred Hutchinson Cancer Center received a $716,319 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded June 11, 2026, with an ultimate completion date of May 31, 2031. The grant funds research and development of optimized CD45-targeted Astatine-211 radioimmunotherapy (RIT) for malignant and non-malignant blood disorders. The research builds on prior Phase 3 clinical validation of Iodine-131-based CD45 RIT and...

Federal Project Grant Award Summary Emory University received a $158,899 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded June 20, 2025, with completion targeted for May 31, 2027. This award supports the development of an innovative Simultaneous Intensity Energy Modulation and Compensation (SIEMAC) optimization platform and integrated quality assurance (QA) system for conformal flash proton therapy treatment of central lung...